Novavax vaccine – Development and deployment stages explained
Novavax’s COVID-19 vaccine is known by several names globally, including NVX-CoV2373 and Nuvaxovid in some regions. The vaccine uses a tiny piece of the SARS-CoV-2 virus’s spike protein as its primary antigen. This spike protein is the part of the virus that lets it enter human cells and enhance the body’s immune response. The vaccine further includes an adjuvant called Matrix-M. Here are a few details about the vaccine’s development and deployment. Preclinical development Novavax began developing the vaccine in early 2020 utilizing its nanoparticle technology platform. The company identified a stabilized SARS-CoV-2 spike protein as its antigen and combined it with an adjuvant (Matrix-M) to enhance the immune response. Phase 1 and phase 2 trials Novavax initially conducted clinical trials in two phases to evaluate the vaccine’s safety and immunogenicity. These trials involved a relatively small number of participants and aimed to determine the appropriate dosage. Phase 3 clinical trials In the latter half of 2020 and early 2021, Novavax initiated large-scale phase 3 clinical trials to assess the vaccine’s efficacy in preventing COVID-19. These trials involved thousands of participants in multiple countries. Authorization and approval The Novavax vaccine, like other COVID-19 vaccines, required regulatory authorization or approval by a country’s authorities before it could be used.